Iclepertin
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Iclepertin
- Molecular weight
- 512.43
- Structure (SMILES)
- C[C@@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1C[C@@H]2C[C@]2(c2cc(C(F)(F)F)on2)C1)C(F)(F)F
- bi 425809
- BI 425809
- BI 425809 tablet
- iclepertin
- Iclepertin
- iclepertin (BI 425809)
- iclepertin [INN]
- ICLEPERTIN [USAN]
- Iclepertin [WHO-DD]
- iclepertin inn
- iclepertin usan
- iclepertin who dd
- CAS registry numbers
- 1421936-85-7
- ChEMBL ID
- CHEMBL5314576
- InChIKey
- MYHDQTVHHMSLEF-DDBGAENHSA-N
- PubChem compound IDs
- 155259577
- FDA ingredient codes (UNII)
- M43ZDU10DD
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- iclepertin
- Type
- Synthetic organic
- Drug name stem
- -pertin
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- GlyT1
- Gene symbol
- SLC6A9
- Protein identifier
- P48067
- Median affinity
- 8.3
- Affinity units
- pIC50
- Condition
- Renal Insufficiency
- Highest recorded phase
- 1
- Condition identifier
- HP:0000083
- Subject identifier
- D051437
- Condition
- Cognitive Dysfunction
- Highest recorded phase
- 1
- Condition identifier
- HP:0001268
- Subject identifier
- D060825
- Condition
- Alzheimer Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004975
- Subject identifier
- D000544
- Condition
- Schizophrenia
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005090
- Subject identifier
- D012559
- Condition identifier
- HP_0000083
- Highest recorded phase
- 1
- Condition identifier
- HP_0001268
- Condition identifier
- HP_0001399
- Highest recorded phase
- 1
- Condition identifier
- HP_0100543
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004975
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005090
- Highest recorded phase
- 3
- NCT02788513
- NCT02832037
- NCT03859973
- NCT04846868
- NCT04846881
- NCT04860830
- NCT05211947
- NCT05718843
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 0
- Polar surface area
- 89.71
- Calculated partition coefficient (ALogP)
- 3.84
- Calculated partition coefficient (XLogP)
- 3.5
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 5
- Heavy atoms
- 34
- Molecular formula
- C20H18F6N2O5S
- Monoisotopic mass
- 512.08406182
- Natural product
- No
- Recorded assays
- 11
- Active assays
- 1
Active assay types
- Confirmatory
Related records
Trials (27)
- A Study in Healthy Men and Women to Test Which Effects Donepezil and BI 425809 Have on Each Other
- A Study in Healthy Men and Women to Test Which Effects Memantine and BI 425809 Have on Each Other
- A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body
- A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet
- A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the Blood
- A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
- A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood
- A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood
- A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 425809 in the Blood
- A Study in Healthy People to Test How BI 425809 is Taken up in the Body When Taken With or Without Food
- A Study in Healthy People to Test Whether Iclepertin Has an Effect on Cardiac Safety
- A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood
- A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems
- A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems
- A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
- BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
- Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia
- Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)
- Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
- CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
In development for (3)
- Alzheimer disease Phase 2
- Kidney failure Phase 1
- Schizophrenia Phase 3